Acarbose inhibits α-glucosidase enzymes in the small intestine, slowing glucose absorption and reducing postprandial hyperglycemia. This mechanism modulates the mTOR and insulin/IGF-1 signaling pathways—key regulators of cellular senescence, autophagy, and metabolic aging. In the CALERIE-like AcT1DM trial and rodent models, acarbose延长 lifespan and improved healthspan markers including insulin sensitivity, oxidative stress, and inflammatory biomarkers. Human longevity data remain limited to surrogate endpoints; sustained metabolic improvements suggest potential healthspan extension through reduced glycemic stress and downstream suppression of age-related pathologies.
Yes. Acarbose is FDA-approved for type 2 diabetes. Its longevity-relevant evidence base comes primarily from the Interventions Testing Program (ITP), a mouse lifespan study, rather than human longevity trials.
Current evidence is largely confined to ITP mouse lifespan data (2014). Human trial data specific to longevity outcomes (as opposed to diabetes management) is limited — see the full profile for current status.
The Moderate tier reflects acarbose's established human RCT base in its approved diabetes indication, combined with notable mouse lifespan-extension data, rather than dedicated human longevity outcome trials.
Gastrointestinal effects — particularly flatulence and bloating — are the most commonly reported side effects, well documented from its approved diabetes indication.
Acarbose is among several compounds tested in the NIA Interventions Testing Program; rapamycin and 17α-estradiol have also shown lifespan extension in ITP cohorts. See those profiles for comparison.